سعر إيميجراند 0.075 مجم/1.5 مل فيال للحقن الوريدي 2024

Emegrand palonosetron 0.075 mg/1.5 mL IV vial (Delta Grand Pharma) — PONV-strength presentation per Egyptian directories.

• Prevention of acute and delayed nausea/vomiting associated with initial and repeat courses of moderately or highly emetogenic cancer chemotherapy; prevention of PONV for up to 24 hours after surgery (US palonosetron IV).Population: Adults; paediatric chemo indications per US label from 1 monthDailyMed / FDA

• Most common (≥5%): headache, constipation; also bradycardia, QT prolongation reports, injection-site reactions (US labelling).International label, same formulation · DailyMed / FDA

• Known hypersensitivity to palonosetron or any component (US labelling).International label, same formulation · DailyMed / FDA

• Hypersensitivity including anaphylaxis; serotonin syndrome with serotonergic drugs; QT prolongation risk class effect for 5-HT3 antagonists — ECG monitoring if risk factors (US labelling).International label, same formulation · DailyMed / FDA

• Serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans, tramadol, etc.)MajorIncreased risk of serotonin syndrome; monitor and discontinue if suspected.DailyMed / FDA

• Limited human data; animal studies do not indicate direct reproductive toxicity at exposures relevant to clinical doses — use only if needed (US labelling).International label, same formulation · DailyMed / FDA
• Unknown whether palonosetron is excreted in human milk; consider interruption vs maternal need (US labelling).International label, same formulation · DailyMed / FDA

• Palonosetron: Blocks serotonin 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone.